Sulofenur (BioDeep_00000650727)
代谢物信息卡片
Sulofenur
化学式: C16H15ClN2O3S (350.0491870000001)
中文名称: 磺氯苯脲
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC2=C(C1)C=C(C=C2)S(=O)(=O)NC(=O)NC3=CC=C(C=C3)Cl
InChI: InChI=1S/C16H15ClN2O3S/c17-13-5-7-14(8-6-13)18-16(20)19-23(21,22)15-9-4-11-2-1-3-12(11)10-15/h4-10H,1-3H2,(H2,18,19,20)
描述信息
C274 - Antineoplastic Agent > C2186 - Diarylsulfonylurea Compound
D000970 - Antineoplastic Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xiangming Guan, Brianna N Hoffman, Douglas C McFarland, Kysa K Gilkerson, Chandradhar Dwivedi, Angela K Erickson, Scott Bebensee, Jill Pellegrini. Glutathione and mercapturic acid conjugates of sulofenur and their activity against a human colon cancer cell line.
Drug metabolism and disposition: the biological fate of chemicals.
2002 Mar; 30(3):331-5. doi:
10.1124/dmd.30.3.331. [PMID: 11854154] - Claudia M Jochheim, Margaret R Davis, Kathleen M Baillie, William J Ehlhardt, Thomas A Baillie. Glutathione-dependent metabolism of the antitumor agent sulofenur. Evidence for the formation of p-chlorophenyl isocyanate as a reactive intermediate.
Chemical research in toxicology.
2002 Feb; 15(2):240-8. doi:
10.1021/tx0155698. [PMID: 11849051] - A Krarup-Hansen, H Pedersen, E Andersen, H Andersen, H H Hansen. Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours.
Investigational new drugs.
1997; 15(2):147-51. doi:
10.1023/a:1005864907544. [PMID: 9220294] - H Gu, M W Smith, P C Phelps, I K Berezesky, R L Merriman, G B Boder, B F Trump. H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment.
Cancer letters.
1996 Sep; 106(2):199-205. doi:
10.1016/0304-3835(96)04314-5. [PMID: 8844973] - P C Phelps, C J Best, I K Berezesky, R L Merriman, L R Tanzer, G B Boder, B F Trump. Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines.
Cancer letters.
1995 Oct; 97(1):7-15. doi:
10.1016/0304-3835(95)03942-p. [PMID: 7585481] - P J Houghton, J Sosinski, J H Thakar, G B Boder, G B Grindey. Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur.
Biochemical pharmacology.
1995 Mar; 49(5):661-8. doi:
10.1016/0006-2952(94)00501-c. [PMID: 7887981] - R M Schultz, S L Andis, J E Toth, G B Boder, S M Rinzel, G B Grindey. Effect of albumin on antitumor activity of diarylsulfonylureas.
Anticancer research.
1993 Nov; 13(6A):1939-43. doi:
NULL. [PMID: 8297099] - M Mahjoubi, J Kattan, M Bonnay, H Schmitt, J P Droz. Phase II trial of LY 186641 in advanced renal cancer.
Investigational new drugs.
1993 Nov; 11(4):323-8. doi:
10.1007/bf00874431. [PMID: 7726992] - W J Ehlhardt, H R Sullivan, P G Wood, J M Woodland, M Hamilton, C Hamilton, D Cornpropst, G B Grindey, J F Worzalla, J R Bewley. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.
Journal of pharmaceutical sciences.
1993 Jul; 82(7):683-8. doi:
10.1002/jps.2600820703. [PMID: 8360840] - J Sosinski, J H Thakar, G S Germain, F C Harwood, P J Houghton. Proliferation-dependent and -independent cytotoxicity by antitumor diarylsulfonylureas. Indication of multiple mechanisms of drug action.
Biochemical pharmacology.
1993 May; 45(10):2135-42. doi:
10.1016/0006-2952(93)90027-t. [PMID: 8512595] - D C Talbot, I E Smith, M C Nicolson, T J Powles, D Button, J Walling. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.
Cancer chemotherapy and pharmacology.
1993; 31(5):419-22. doi:
10.1007/bf00686159. [PMID: 8431978] - R M Schultz, R L Merriman, J E Toth, J E Zimmermann, L W Hertel, S L Andis, D E Dudley, P G Rutherford, L R Tanzer, G B Grindey. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.
Oncology research.
1993; 5(6-7):223-8. doi:
NULL. [PMID: 8123942] - C W Taylor, D S Alberts, Y M Peng, T M McCloskey, M Matzner, D J Roe, P M Plezia, G B Grindey, M Hamilton, D Seitz. Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
Journal of the National Cancer Institute.
1992 Dec; 84(23):1798-802. doi:
10.1093/jnci/84.23.1798. [PMID: 1433369] - A Kamthan, J H Scarffe, J Walling, S Hatty, B Peters, R Coleman, J F Smyth. A phase II study of sulofenur (LY186641) in gastric cancer.
Anti-cancer drugs.
1992 Aug; 3(4):331-5. doi:
10.1097/00001813-199208000-00003. [PMID: 1421428] - M E O'Brien, J Hardy, S Tan, J Walling, B Peters, S Hatty, E Wiltshaw. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.
Cancer chemotherapy and pharmacology.
1992; 30(3):245-8. doi:
10.1007/bf00686324. [PMID: 1628377] - B Weinerman, E Eisenhauer, D Stewart, W Mertens, I Tannock, P Venner, R Spaulding. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
1992 Jan; 3(1):83-4. doi:
10.1093/oxfordjournals.annonc.a058081. [PMID: 1606075] - W J Ehlhardt. Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human.
Drug metabolism and disposition: the biological fate of chemicals.
1991 Mar; 19(2):370-5. doi:
. [PMID: 1676639] - K R Hande, J Kuttesch, M Hamilton, W Satterlee, L Jackson, G Grindey, J D Hainsworth. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
Cancer research.
1990 Jul; 50(13):3910-4. doi:
NULL. [PMID: 2354440] - P J Houghton, F C Bailey, G S Germain, G B Grindey, B C Witt, J A Houghton. N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells.
Cancer research.
1990 Jan; 50(2):318-22. doi:
NULL. [PMID: 2295071] - C W Taylor, D S Alberts, M A Ketcham, W G Satterlee, M T Holdsworth, P M Plezia, Y M Peng, T M McCloskey, D J Roe, M Hamilton. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1989 Nov; 7(11):1733-40. doi:
10.1200/jco.1989.7.11.1733. [PMID: 2809686] - J D Hainsworth, K R Hande, W G Satterlee, J Kuttesch, D H Johnson, G Grindey, L E Jackson, F A Greco. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).
Cancer research.
1989 Sep; 49(18):5217-20. doi:
NULL. [PMID: 2766290]